<DOC>
	<DOCNO>NCT02243917</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 study orally administer CB-5083 adult subject advance metastatic solid tumor . The study conduct 2 part : initial Dose Escalation Phase ( Phase 1a ) CB-5083 subject advance metastatic solid tumor progress non-responsive available therapy standard therapy exists , follow Dose Expansion Phase ( Phase 1b ) include 1 4 arm : one arm subject RAS mutate mCRC ; optionally , sponsor discretion , 3 additional arm may add subject advanced RCC , advance pNET , solid tumor mutation RAS-MAPK pathway .</brief_summary>
	<brief_title>A Phase 1 Study Evaluating CB-5083 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>The objective Dose Escalation Phase determine safety , tolerability , PK pharmacodynamic profile , MTD and/or RP2D , effect feed vs. fast state bioavailability orally administer CB-5083 . The objective dose expansion phase confirm safety tolerability RP2D , ass PK pharmacodynamic profile evaluate preliminary anti-tumor activity CB-5083 subject tumor biologic plausibility unique sensitivity CB-5083 mechanism action ( MOA ) base pre-clinical data . The objective Food Effect Stage determine effect feed vs. fast state bioavailability orally administer CB-5083 .</detailed_description>
	<criteria>Inclusion Criteria All Phases : 1 . Males females ≥18 year age ; 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤1 3 . Acceptable bone marrow organ function screen describe : 1 . ANC ≥ 1,500/µL ; 2 . Platelet count ≥ 100,000/µL ; 3 . Total bilirubin ≤ 1.5 × ULN ≤ 3.0 × ULN subject hereditary benign hyperbilirubinemia ; 4 . AST ( SGOT ) ≤ 3 × ULN ( ≤ 5 × ULN liver metastasis present ) ; 5 . ALT ( SGPT ) ≤ 3 × ULN ( ≤ 5 × ULN liver metastasis present ) ; 6 . Serum creatinine ≤ 1.5 mg/dL measure creatinine clearance ³ 60 mL/min accord CockcroftGault formula 4 . Left ventricular ejection fraction inform ( LVEF ) ≥ 55 % ; 5 . Ability swallow retain oral medication ; 6 . Negative serum betahuman Chorionic Gonadotropin ( βhCG ) test woman childbearing potential ( WOCBP ) ; Note , subject must agree use dual barrier contraceptive method ; 7 . Willing able provide write informed consent comply requirement study ; 8 . Phase 1a Dose Escalation Histologically confirm advanced solid tumor standard therapy exist longer effective 9 . Food Effect Stage willing able ingest standard meal 10 . Phase 1b All Expansion Cohorts Evidence measurable disease per RECIST , v1.1 . Measurable disease define lesion accurately measure least 1 dimension ( long diameter record ) minimum size 10 mm compute tomography ( CT ) scan ; 11 . Phase 1b All Expansion Cohorts Prior treatment embolization ablative therapy allow measurable disease remain outside treated area definitive progression treat lesion . There limit number prior procedure ; 12 . Phase 1b Dose Expansion RAS Mutated mCRC Arm Histologically confirm colorectal cancer KRAS NRAS mutation exon 2,3 4 metastatic unresectable ; 13 . Phase 1b Dose Expansion RAS Mutated mCRC Arm At least 2 prior systemic therapy treatment metastatic colorectal cancer . Neoadjuvant adjuvant therapy may count part prior therapy requirement . At least 7 subject naïve treatment regorafenib ; 14 . Phase 1b Optional Dose Expansion Advanced RCC Arm Histologically confirm metastatic renal cell carcinoma ; 15 . Phase 1b Optional Dose Expansion Advanced RCC Arm Must receive 2 prior therapy metastatic RCC , include vascular endothelial growth factor receptor ( VEGFR ) tyrosine kinase inhibitor ( TKI ) immune checkpoint inhibitor ( ie antiPD1 ) ( approve available commercial use local country ) . At least 7 subject naïve treatment prior inhibitor mammalian target rapamycin ( mTOR ) ( eg . everolimus ) ; 16 . Phase 1b Optional Dose Expansion pNET Arm Histologically confirm lowgrade intermediategrade , unresectable metastatic pNET tumor standard therapy exist longer effective . Functional nonfunctional tumor include ; 17 . Phase 1b Optional Dose Expansion RASMAPK Pathway Mutation Arm Histologically confirm malignancy RASMAPK pathway mutation metastatic unresectable standard therapy exist longer effective . At least 10 subject nonsmall cell lung cancer ( NSCLC ) enrol arm . Exclusion Criteria All Phases 1 . Any prior treatment ( exception somatostatin analogue , allow study pNET subject investigator discretion pNET subject ) chemotherapy , immunomodulatory drug therapy , antineoplastic hormonal therapy ( unless dose stable 3 month prior Baseline remain stable study ) , immunosuppressive therapy , corticosteroid ( unless administer prevent contrast material reaction radiographic procedure ) receive within past 28 day 5 halflives , whichever short ; 2 . Presence acute chronic toxicity result prior chemotherapy , exception alopecia , resolve ≤ grade 1 , determine NCI CTCAE v 4.0 ( http : //evs.nci.nih.gov/ftp1/CTCAE/About.html ) ; 3 . Received radiotherapy within last 21 day ( limited palliative radiation allow ≥ 14 day prior ) ; 4 . Subjects primary brain tumor known central nervous system ( CNS ) metastases ; 5 . Major surgery &lt; 28 day start treatment ( major surgery define procedure require general anesthesia ) ; 6 . Minor surgery &lt; 14 day start treatment ( insertion vascular access device consider major minor surgery ) ; 7 . Active infection require systemic therapy ; 8 . Known human immunodeficiency virus ( HIV ) positive acquire immunodeficiency syndromerelated illness ; 9 . Uncontrolled congestive heart failure , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug ; 10 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female ; 11 . History esophageal bleeding due varix ; 12 . Gastrointestinal disease may interfere absorption orallyadministered drug ; 13 . History inflammatory bowel disease illness result chronic diarrhea ; 14 . Known achlorhydria history gastrointestinal surgery could reduce acidity stomach ; 15 . Acute pancreatitis cholecystitis within 6 month prior Baseline ; 16 . Cirrhosis severe liver dysfunction ( ChildPugh Class B C ) ; 17 . Previous concomitant malignancy , except basalcell squamous cell carcinoma skin carcinomainsitu uterine cervix . Subjects malignancy eligible remain disease free least 2 year prior study entry ; 18 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , Investigator 's opinion , would make subject inappropriate entry study ; 19 . Use investigational agent within 28 day 5 halflives ( whichever short ) prior Baseline ; 20 . A condition expect require concomitant use medication list prohibited study ; 21 . Pregnant lactate female ; 22 . Women childbearing potential , men partner woman childbearing potential , unless agree use dual barrier contraceptive method , Investigator 's opinion , effective adequate subject 's circumstance study drug 3 month afterward ; 23 . Grade 3 4 eye disorder study entry , unless stable longstanding ( &gt; 3 month ) unlikely interfere protocolrequired ophthalmology assessment ; 24 . Phase 1b Optional Dose Expansion pNET Arm Poorly differentiate pNET ; 25 . Phase 1b Optional Dose Expansion RASMAPK Pathway Mutation Arm Subjects primary pancreatic cancer primary RAS mutate colorectal cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>